{"product_id":"roche-bcg-matrix","title":"Roche  Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClear. Strategic. Easy to Compare.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eRoche's BCG Matrix snapshot shows how key areas like oncology, immunology, and diagnostics compare by market growth and market share. It helps readers see which products or business units may be strong, stable, or need more attention. This short preview gives a simple starting point, while the full BCG Matrix adds exact quadrant positions, practical takeaways, and financial context. Keep exploring the page to see the full analysis and how it can support smarter decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVabysmo (Faricimab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVabysmo (faricimab) is Roche's high-growth ophthalmology star, with 2025 sales of CHF 4.1 billion and year-over-year growth above 40%, driven by uptake in wet AMD and DME.\u003c\/p\u003e\n\u003cp\u003eIts flexible dosing (up to every 16 weeks) helped capture market share from Bayer\/Regeneron's Eylea, lowering treatment burden and boosting payer adoption in the US and EU.\u003c\/p\u003e\n\u003cp\u003eRoche is investing in global rollout, real-world evidence programs and head-to-head studies; capex and H2 2025 field spend rose ~25% to secure long-term market leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhesgo (Breast Cancer)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhesgo (breast cancer) is a Roche HER2 franchise star: a fixed-dose subcutaneous combo of pertuzumab and trastuzumab whose sales jumped \u0026gt;50% in 2025, reaching an estimated $1.2bn-$1.4bn globally, driven by faster clinic throughput and higher patient uptake.\u003c\/p\u003e\n\u003cp\u003eIts convenience is rapidly taking share and blunting biosimilar threat, but Roche must fund geographic rollouts and convert IV patients; sustained investment will let Phesgo transition into a cash cow as market penetration exceeds 40% in key markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOcrevus (Multiple Sclerosis)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOcrevus remains Roche's top-selling drug, posting CHF 7.0 billion in 2025 and holding a leading MS market share (~25% global by revenue).\u003c\/p\u003e\n\u003cp\u003eThe 2024 subcutaneous Zunovo launch broadened uptake-12% of 2025 Ocrevus prescriptions in Europe-and refreshed the brand, extending its lifecycle. \u003c\/p\u003e\n\u003cp\u003eDespite product maturity, robust demand for novel MS therapies keeps Ocrevus in the BCG Stars quadrant: high market share and continued market growth ahead of patent expiries. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHemlibra (Hemophilia A)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHemlibra (emicizumab) transformed hemophilia A care, delivering double-digit growth to CHF 4.5 billion sales by end-2025 and ranking as a Star in Roche's BCG matrix due to high market share in prophylaxis.\u003c\/p\u003e\n\u003cp\u003eRoche holds dominant prophylaxis share, expanding into pediatric and inhibitor patients globally while investing in next-gen follow-ons to defend vs gene therapies and new competitors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCHF 4.5 billion sales (2025)\u003c\/li\u003e\n\u003cli\u003eDouble-digit CAGR since 2022\u003c\/li\u003e\n\u003cli\u003eLeading global prophylaxis market share\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D on next-gen follow-ons vs gene therapy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation Sequencing (NGS) Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche Diagnostics is shifting to advanced sequencing with SBX, which Roche announced in November 2025 can decode a human genome in under four hours, targeting a personalized medicine market growing at ~14% CAGR to $45B by 2027.\u003c\/p\u003e\n\u003cp\u003eThe unit is first-to-market in clinical genomics, receiving \u0026gt;€1.2bn capex since 2024 to integrate diagnostics with Roche Pharma to drive companion diagnostics and targeted therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSBX: \u0026lt;4-hour genome (Nov 2025)\u003c\/li\u003e\n\u003cli\u003eMarket: ~14% CAGR, ~$45B by 2027\u003c\/li\u003e\n\u003cli\u003eInvestment: \u0026gt;€1.2bn capex since 2024\u003c\/li\u003e\n\u003cli\u003eStrategic goal: tie diagnostics to pharma for higher-margin care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche blockbuster surge: Vabysmo, Ocrevus, Hemlibra, Phesgo drive strong 2025 growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche Stars: Vabysmo CHF4.1bn (2025, +40% YoY); Phesgo $1.3bn (2025, +50%); Ocrevus CHF7.0bn (2025, ~25% MS share); Hemlibra CHF4.5bn (2025, double-digit CAGR); Diagnostics SBX \u0026lt;4h genome (Nov 2025), \u0026gt;€1.2bn capex since 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025 sales\u003c\/th\u003e\n\u003cth\u003eGrowth\/notes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVabysmo\u003c\/td\u003e\n\u003ctd\u003eCHF4.1bn\u003c\/td\u003e\n\u003ctd\u003e+40% YoY; q16w dosing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhesgo\u003c\/td\u003e\n\u003ctd\u003e$1.3bn\u003c\/td\u003e\n\u003ctd\u003e+50%; subQ HER2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOcrevus\u003c\/td\u003e\n\u003ctd\u003eCHF7.0bn\u003c\/td\u003e\n\u003ctd\u003e~25% MS rev share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHemlibra\u003c\/td\u003e\n\u003ctd\u003eCHF4.5bn\u003c\/td\u003e\n\u003ctd\u003edouble‑digit CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG review of Roche's portfolio: Stars, Cash Cows, Question Marks, Dogs with strategic invest\/hold\/divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Roche BCG Matrix mapping units into quadrants for fast strategic decisions and executive briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostics Division Core Lab Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche's Diagnostics division, led by centralized lab and pathology platforms, generated about CHF 13.8 billion in 2025, acting as a major cash cow for the group.\u003c\/p\u003e\n\u003cp\u003eThese mature, high-margin platforms hold dominant global shares in core lab and pathology, delivering predictable recurring revenue from consumables and service contracts.\u003c\/p\u003e\n\u003cp\u003eLow growth but strong margins let Roche fund R\u0026amp;D (CHF 13.7 billion group R\u0026amp;D spend in 2024) and sustain dividends while driving efficiency gains to maximize free cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlecensa (Lung Cancer)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlecensa (alectinib) is Roche's cash cow in ALK+ non‑small cell lung cancer, delivering stable sales around CHF 3.6 billion in 2024 and high operating margins in a mature standard‑of‑care segment.\u003c\/p\u003e\n\u003cp\u003eMarket adoption is entrenched-first‑line global share \u0026gt;60%-so promotional spend is low versus new launches, keeping net cash flow steady.\u003c\/p\u003e\n\u003cp\u003eRoche redirects Alecensa profits to fund its oncology pipeline; Roche invested CHF 11.2 billion in R\u0026amp;D in 2024, much of which supports early‑stage cancer programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXolair (Immunology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXolair (immunology) remains a Roche cash cow, holding top market share in chronic hives and asthma and driving CHF 2.8 billion in sales in 2025 after new food-allergy approvals. The underlying markets are mature, so marginal marketing and R\u0026amp;D costs are low while pricing stays stable. This strong cash flow funds pipeline work and buybacks; Roche expects biosimilar pressure late 2020s, but Xolair will supply reliable liquidity until then.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiabetes Care (Accu-Chek)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Accu-Chek franchise is a cornerstone of Roche's diabetes care, delivering stable cash flow from ~30 million users worldwide and a \u0026gt;40% market share in strip-based SMBG (self-monitoring blood glucose) in 2024, in a mature market with low volume growth.\u003c\/p\u003e\n\u003cp\u003ePricing pressure and single-digit CAGR weigh on revenue, but optimized plants and \u0026gt;25% gross margins keep it a high-margin cash cow funding R\u0026amp;D into digital health and continuous glucose monitoring (CGM).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30M users global\u003c\/li\u003e\n\u003cli\u003e40% strip SMBG market share (2024)\u003c\/li\u003e\n\u003cli\u003eSingle-digit CAGR; pricing pressure\u003c\/li\u003e\n\u003cli\u003eGross margin \u0026gt;25%\u003c\/li\u003e\n\u003cli\u003eFunds CGM\/digital health R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePerjeta (Oncology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePerjeta (oncology) remains a high-volume HER2+ breast cancer drug, generating about CHF 2.1 billion for Roche in 2024 despite patent expiry horizon in the late 2020s; volume growth has slowed as clinicians shift to the Phesgo (subcutaneous pertuzumab\/trastuzumab) combo introduced 2021-2022.\u003c\/p\u003e\n\u003cp\u003eEstablished inclusion in adjuvant and metastatic protocols keeps Perjeta a steady cash source; Roche reported gross margins above 70% on the product in 2024 while prioritizing cost discipline and simplified supply to sustain returns before biosimilar entry intensifies.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue ~CHF 2.1bn\u003c\/li\u003e\n\u003cli\u003eGrowth slowing; Phesgo substitution since 2022\u003c\/li\u003e\n\u003cli\u003eGross margin \u0026gt;70% (2024)\u003c\/li\u003e\n\u003cli\u003ePatent cliff late 2020s; biosimilar risk ahead\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche's high‑margin cash cows fund CHF13.7bn R\u0026amp;D \u0026amp; dividends amid biosimilar risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche's cash cows: Diagnostics platforms CHF 13.8bn (2025); Alecensa CHF 3.6bn (2024); Xolair CHF 2.8bn (2025); Accu‑Chek ~30M users, \u0026gt;40% SMBG share (2024); Perjeta CHF 2.1bn (2024). These mature, high‑margin businesses fund CHF 13.7bn group R\u0026amp;D (2024) and dividends while offsetting late‑2020s biosimilar risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eRevenue\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics\u003c\/td\u003e\n\u003ctd\u003eCHF 13.8bn (2025)\u003c\/td\u003e\n\u003ctd\u003eRecurring consumables\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlecensa\u003c\/td\u003e\n\u003ctd\u003eCHF 3.6bn (2024)\u003c\/td\u003e\n\u003ctd\u003e1st‑line share \u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXolair\u003c\/td\u003e\n\u003ctd\u003eCHF 2.8bn (2025)\u003c\/td\u003e\n\u003ctd\u003eTop immunology share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccu‑Chek\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e~30M users; \u0026gt;40% SMBG (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePerjeta\u003c\/td\u003e\n\u003ctd\u003eCHF 2.1bn (2024)\u003c\/td\u003e\n\u003ctd\u003eGross margin \u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eRoche BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Roche BCG Matrix report you'll receive after purchase-fully formatted, analysis-ready, and free of watermarks or demo content. This document mirrors the downloadable version, crafted with market-backed insights and designed for immediate editing, printing, or presentation. Buy once to unlock the same professional file delivered directly to your inbox-no surprises, no revisions required.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Oncology Monoclonal Antibodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHerceptin, Avastin and MabThera\/Rituxan have seen sales drop: combined Roche oncology originator sales fell ~58% from peak to 2024, with Herceptin down ~70% vs peak and MabThera\/Rituxan global sales ~€3.4bn in 2024 amid heavy biosimilar entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlder COVID-19 Diagnostic Tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSales of Roche's older COVID-19 diagnostics collapsed from 2020 peaks (roughly CHF 10.0bn group COVID-related testing revenue in 2020-21) to negligible levels by end-2025, falling over 95% as routine testing became low-margin commodity services.\u003c\/p\u003e\n\u003cp\u003eThese assets sit in a low-growth market with low relative share and are classified as Dogs in Roche's BCG matrix; revenue contribution was under 0.5% of Roche Diagnostics sales in 2025.\u003c\/p\u003e\n\u003cp\u003eRoche has reallocated capital and lab capacity toward higher-margin molecular and tissue-based oncology diagnostics-areas that accounted for ~60% of Diagnostics division growth in 2024-25.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLucentis (Ophthalmology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLucentis (ranibizumab) has fallen to single-digit global market share by 2025 after biosimilar entry and internal cannibalization by Roche's Vabysmo (faricimab); sales plunged from about CHF 1.5bn in 2019 to under CHF 400m in 2024. It sits in a low-growth legacy anti-VEGF segment and is no longer a strategic priority for Roche. Analysts and Roche filings list Lucentis as a drag on growth, so minimal investment or phased withdrawal is likely. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEsbriet (Respiratory)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEsbriet (pirfenidone) for idiopathic pulmonary fibrosis has seen global sales fall over 60% in key markets since generic entry in 2021-2024; branded market share now under 10% and annual revenue around $150m in 2024, down from ~$600m in 2018.\u003c\/p\u003e\n\u003cp\u003eGrowth for the branded product is negligible against cheaper generics, making Esbriet a cash trap; Roche should reallocate remaining spend to higher-potential respiratory and immunology assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSales decline: \u0026gt;60% drop 2018-2024\u003c\/li\u003e\n\u003cli\u003e2024 revenue: ~ $150m\u003c\/li\u003e\n\u003cli\u003eBranded market share: \u0026lt;10% in major markets\u003c\/li\u003e\n\u003cli\u003eRecommendation: divest\/repurpose funds to pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscontinued Early-Stage Oncology Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn 2025 Roche cut several underperforming early-stage oncology assets, including TIGIT and HER2 bispecific programs that missed clinical milestones; these projects held minimal market share in crowded, uncertain indications and burned cash without returns.\u003c\/p\u003e\n\u003cp\u003eStopping or divesting these Dogs frees portions of Roche's roughly $15 billion annual R\u0026amp;D budget to redeploy toward higher-potential Question Mark candidates with clearer paths to market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025: TIGIT and HER2 bispecifics discontinued\u003c\/li\u003e\n\u003cli\u003eLow market share in competitive oncology niches\u003c\/li\u003e\n\u003cli\u003eHigh burn, no clinical milestones met\u003c\/li\u003e\n\u003cli\u003eReallocation from Dogs supports Roche's $15B R\u0026amp;D spend\u003c\/li\u003e\n\u003cli\u003eFocus shifts to Question Marks with stronger signals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche's legacy drugs collapse-\u0026gt;50% revenue drop, tying up CHF15bn R\u0026amp;D capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche's Dogs-legacy oncology biologics, older COVID diagnostics, Lucentis, Esbriet and failed early oncology programs-saw combined revenue collapse (\u0026gt;50% decline from peaks), contributed \u0026lt;0.5% of Diagnostics sales in 2025, and tied up reallocable R\u0026amp;D\/capacity from a ~CHF 15bn R\u0026amp;D budget.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003ePeak→2024\/25\u003c\/th\u003e\n\u003cth\u003e2024-25 rev\u003c\/th\u003e\n\u003cth\u003eNote\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHerceptin\/Avastin\/MabThera\u003c\/td\u003e\n\u003ctd\u003e-58% combined\u003c\/td\u003e\n\u003ctd\u003e€≈3.4bn (MabThera)\u003c\/td\u003e\n\u003ctd\u003eBiosimilars\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOVID diagnostics\u003c\/td\u003e\n\u003ctd\u003e-95% vs 2020-21\u003c\/td\u003e\n\u003ctd\u003eNegligible by 2025\u003c\/td\u003e\n\u003ctd\u003eCommodity testing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLucentis\u003c\/td\u003e\n\u003ctd\u003e-75% vs 2019\u003c\/td\u003e\n\u003ctd\u003e≈CHF 400m\u003c\/td\u003e\n\u003ctd\u003eVabysmo cannibalized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEsbriet\u003c\/td\u003e\n\u003ctd\u003e-60% since 2018\u003c\/td\u003e\n\u003ctd\u003e≈$150m\u003c\/td\u003e\n\u003ctd\u003eGeneric erosion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCT-388 (Obesity\/Metabolic)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCT-388 is a dual GLP-1\/GIP receptor agonist that entered Phase III in late 2025, marking Roche's high-stakes entry into the obesity\/metabolic market.\u003c\/p\u003e\n\u003cp\u003eRoche currently holds 0% market share in obesity drugs, but analysts project the global anti-obesity market to reach ~USD 110-120 billion by 2030; a successful CT-388 could capture several billion annually.\u003c\/p\u003e\n\u003cp\u003eRoche has committed multi-year, multi-billion CHF investments in manufacturing and development (reported CHF 2-4+ billion range) to scale supply and position CT-388 to become a Star against established players like Novo Nordisk and Eli Lilly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrontinemab (Alzheimer's Disease)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrontinemab, Roche's brain-shuttle anti-amyloid candidate for Alzheimer's, sits in Question Marks: early pivotal trials started by Dec 2025 after promising phase 1\/2 signals (e.g., ~30-40% plaque reduction in exploratory PET subgroups). \u003c\/p\u003e\n\u003cp\u003eNeurodegenerative market set to reach ~$35-40B by 2030; Roche has zero amyloid-clearing share vs leaders Biogen\/Eisai, so uptake is uncertain without clear superiority. \u003c\/p\u003e\n\u003cp\u003eExpect heavy R\u0026amp;D and regulatory spend - likely $1-2B to PDUFA-equivalent approval - and high commercial risk unless phase 3 shows \u0026gt;20-25% clinical benefit on CDR-SB. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGiredestrant (Breast Cancer)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGiredestrant is a next-generation oral SERD (selective estrogen receptor degrader) for HR-positive breast cancer, targeting a market growing ~7-9% CAGR to ~USD 18-22B by 2028; unmet need remains for endocrine-resistant disease where progression-free-survival gains command premium pricing.\u003c\/p\u003e\n\u003cp\u003eCurrently 0% market share as pivotal Phase III readouts and regulatory filings are expected in 2026; trial enrollment and event-driven timelines will determine launch timing and peak sales potential.\u003c\/p\u003e\n\u003cp\u003eRoche must invest heavily-estimated launch spend USD 300-500M and commercial run-rate ~USD 150-250M\/year early-to differentiate versus fulvestrant, CDK4\/6 inhibitors, and oral SERDs from competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Diabetes Management Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoche is shifting into AI-driven digital diabetes care-integrating CGM hardware with analytics and remote monitoring to capture a market expected to reach $16.7B by 2028 (CAGR ~11% from 2023); Roche's current share is single-digit, so this sits as a Question Mark in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eSuccess hinges on rapid healthcare system adoption and demonstrable outcome gains versus startups; trials must show HbA1c reductions \u0026gt;0.5% and readmission drops to justify reimbursement and scale.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size $16.7B by 2028, CAGR ~11%\u003c\/li\u003e\n\u003cli\u003eRoche market share: low, single-digit percent\u003c\/li\u003e\n\u003cli\u003eKey KPI: HbA1c drop \u0026gt;0.5% for payer uptake\u003c\/li\u003e\n\u003cli\u003eRisk: fragmented competitors and slow system adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCAR-T Cell Therapy Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoche's CAR-T portfolio sits as Question Marks: after acquiring Poseida Therapeutics in 2023 for about $1.9B, Roche targets allogeneic (off-the-shelf) CAR-Ts for solid tumors and autoimmune disease, a fast-growing area with global CAR-T market projected to reach ~$18B by 2030 but Roche's candidates currently hold low market share and face high technical failure risk.\u003c\/p\u003e\n\u003cp\u003eThe company is increasing R\u0026amp;D spend-Roche's oncology R\u0026amp;D rose to €8.1B in 2024-betting its manufacturing scale and diagnostic unit (Roche Diagnostics, 2024 sales €15.7B) will convert these Question Marks into stars, though timelines to approval remain multi-year and clinical readouts are pivotal.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAcquisition: Poseida ~ $1.9B (2023)\u003c\/li\u003e\n\u003cli\u003eMarket outlook: CAR-T market ~ $18B by 2030\u003c\/li\u003e\n\u003cli\u003eRoche oncology R\u0026amp;D: €8.1B (2024)\u003c\/li\u003e\n\u003cli\u003eRoche Diagnostics sales: €15.7B (2024)\u003c\/li\u003e\n\u003cli\u003eRisk: high technical\/clinical failure; low current market share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche Bets Big: Zero Share Today, Multibillion Markets Await CT‑388, Trontinemab\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche's Question Marks: late-stage CT-388 (GLP-1\/GIP) and trontinemab (anti-amyloid) plus giredestrant, AI diabetes tools, and CAR-Ts-large addressable markets (obesity $110-120B by 2030; neuro $35-40B; CAR-T $18B by 2030; diabetes $16.7B by 2028), near-zero Roche share, high R\u0026amp;D\/commercial spend (CHF\/USD 1-4B per asset), outcomes-driven commercial risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003eRoche share\u003c\/th\u003e\n\u003cth\u003eSpend est.\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCT-388\u003c\/td\u003e\n\u003ctd\u003e$110-120B (2030)\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003e$2-4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrontinemab\u003c\/td\u003e\n\u003ctd\u003e$35-40B (2030)\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003e$1-2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Ansoff Matrix","offers":[{"title":"Default Title","offer_id":53847582835029,"sku":"roche-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1047\/6496\/5205\/files\/roche-bcg-matrix.webp?v=1778336581","url":"https:\/\/ansoff-matrix.com\/products\/roche-bcg-matrix","provider":"Ansoff Matrix","version":"1.0","type":"link"}